NCT01451632 - A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

June 30, 2014

Conditions

Colorectal CancerSquamous Cell Head and Neck CancerNon-small Cell Lung CancerTriple Negative Breast CancerOther Tumors With EGFR Dependence

Interventions

DRUG

MM-121

escalating doses MM-121 IV QW

DRUG

Irinotecan

180 mg/m2 IV Q2W

DRUG

Cetuximab

escalating doses cetuximab IV QW

Trial Locations (4)

Chapel Hill

Salt Lake City

San Francisco

Boston